LONG MINI-FUTURE - ELI LILLY & CO | Delayed Deutsche Boerse AG 04:13:18 2024-06-27 EDT | ||
| 49.9 EUR | +0.42% |
|
| Current month | +20.29% | ||
| 1 month | +21.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 49.9 | +0.42% |
| 24-06-26 | 49.69 | -0.48% |
| 24-06-25 | 49.93 | +1.01% |
| 24-06-24 | 49.43 | +1.92% |
| 24-06-21 | 48.5 | +2.58% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 04:13 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6E8X |
| ISIN | DE000VU6E8X3 |
| Date issued | 2023-04-18 |
| Strike | 368.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 50.42 € |
|---|---|
| Lowest since issue | 3.03 € |
| Spread | 0.34 € |
| Spread % | 0.68% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
